Tenaya Therapeutics, Inc. (NASDAQ:TNYA)
| Market Cap | $65.32M-76.7% |
| Revenue (ttm) | $3.03M |
| Net Income | -$101.78M-8.0% |
| EPS | -$0.49+36.7% |
| Shares Out | 227.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,341,574 |
| Open | $0.29 |
| Previous Close | $0.30 |
| Day's Range | $0.28 - $0.32 |
| 52-Week Range | $0.28 - $1.46 |
| Beta | 2.88 |
| Analysts | Buy |
| Price Target | $2.33(+712.98%) |
| Earnings Date | Mar 10, 2027 |
About TNYA
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 10, 2027Earnings report
$TNYA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TNYA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TNYA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TNYA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TNYA Revenue by Segment
| Collaboration revenue | $1.70M | 44.42% |
| Loss on lease termination, net | $1.37M | 35.81% |
| Impairment loss | $666.00K | 17.43% |
| Loss on disposal of property and equipment | $89.00K | 2.33% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TNYA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TNYA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TNYA
| VTIVanguard Morningstar Total Stock Market ETF | $1.49M |
| VXFVanguard Extended Market ETF | $953.15K |
| IBBiShares Biotechnology ETF | $490.55K |
| PRFZInvesco RAFI US 1500 Small-Mid ETF | $88.48K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $52.05K |
| IBBQInvesco Nasdaq Biotechnology ETF | $5.35K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TNYA’s recent data — informational, not investment advice
